Literature DB >> 34144822

Institutional factors associated with adherence to quality measures for stage I and II non-small cell lung cancer.

Rhami Khorfan1, David T Cooke2, Robert A Meguid3, Leah Backhus4, Thomas K Varghese5, Farhood Farjah6, Karl Y Bilimoria7, David D Odell8.   

Abstract

OBJECTIVE: Although previous studies have identified variation in quality lung cancer care, existing quality metrics may not fully capture the complexity of cancer care. The Thoracic Surgery Outcomes Research Network recently developed quality measures to address this. We evaluated baseline adherence to these measures and identified factors associated with adherence.
METHODS: Patients with pathologic stage I and II non-small cell lung cancer from 2010 to 2015 were identified in the National Cancer Database. Patient-level and hospital-level adherence to 7 quality measures was calculated. Goal hospital adherence threshold was 85%. Factors influencing adherence were identified using multilevel logistic regression.
RESULTS: We identified 253,182 patients from 1324 hospitals. Lymph node sampling was performed in 91% of patients nationally, but only 76% of hospitals met the 85% adherence mark. Similarly, 89% of T1b (seventh edition staging) tumors had anatomic resection, with 69% hospital-level adherence. Sixty-nine percent of pathologic stage II patients were recommended chemotherapy, with only 23% hospitals adherent. Eighty-three percent of patients had biopsy before primary radiation, with 64% hospitals adherent. Higher volume and academic institutions were associated with nonadherence to adjuvant chemotherapy and radiation therapy measures. Conversely, lower volume and nonacademic institutions were associated with inadequate nodal sampling and nonanatomic resection.
CONCLUSIONS: Significant gaps continue to exist in the delivery of quality care to patients with early-stage lung cancer. High-volume academic hospitals had higher adherence for surgical care measures, but lower rates for coordination of care measures. This requires further investigation, but suggests targets for quality improvement may vary by institution type.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  lung cancer; outcomes; process measure; quality

Mesh:

Year:  2020        PMID: 34144822      PMCID: PMC8441990          DOI: 10.1016/j.jtcvs.2020.05.123

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   6.439


  20 in total

1.  Patterns of surgical care of lung cancer patients.

Authors:  Alex G Little; Valerie W Rusch; James A Bonner; Laurie E Gaspar; Mark R Green; W Richard Webb; Andrew K Stewart
Journal:  Ann Thorac Surg       Date:  2005-12       Impact factor: 4.330

2.  Defining quality in the surgical care of lung cancer patients.

Authors:  Whitney S Brandt; James M Isbell; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2017-06-09       Impact factor: 5.209

3.  The influence of hospital volume on survival after resection for lung cancer.

Authors:  P B Bach; L D Cramer; D Schrag; R J Downey; S E Gelfand; C B Begg
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

4.  Evaluation of adherence to the Commission on Cancer lung cancer quality measures.

Authors:  David D Odell; Joseph Feinglass; Kathryn Engelhardt; Steven Papastefan; Shari L Meyerson; Ankit Bharat; Malcolm M DeCamp; Karl Y Bilimoria
Journal:  J Thorac Cardiovasc Surg       Date:  2018-11-13       Impact factor: 5.209

5.  Evolution in the Surgical Care of Patients With Non-Small Cell Lung Cancer in the Mid-South Quality of Surgical Resection Cohort.

Authors:  Nicholas R Faris; Matthew P Smeltzer; Fujin Lu; Carrie L Fehnel; Nibedita Chakraborty; Cheryl L Houston-Harris; E Todd Robbins; Raymond S Signore; Laura M McHugh; Bradley A Wolf; Lynn Wiggins; Paul Levy; Vishal Sachdev; Raymond U Osarogiagbon
Journal:  Semin Thorac Cardiovasc Surg       Date:  2016-10-14

6.  Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival.

Authors:  Pamela Samson; Traves Crabtree; Stephen Broderick; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2016-09-21       Impact factor: 4.330

7.  Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer.

Authors:  Sai-Hong Ignatius Ou; Jason A Zell
Journal:  J Thorac Oncol       Date:  2008-08       Impact factor: 15.609

8.  Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer.

Authors:  Jue Wang; Yong Fang Kuo; Jean Freeman; Avi B Markowitz; James S Goodwin
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

9.  Multi-modality mediastinal staging for lung cancer among medicare beneficiaries.

Authors:  Farhood Farjah; David R Flum; Scott D Ramsey; Patrick J Heagerty; Rebecca Gaston Symons; Douglas E Wood
Journal:  J Thorac Oncol       Date:  2009-03       Impact factor: 15.609

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.